Comparison · NCT01342029-deaths
Ranolazine vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ranolazine vs Placebo: deaths from any cause. Trial comparisons, record NCT01342029-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01342029-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0986 | 0.0596 | 0.159 | wilson | |
| Risk in group 2 | 0.0775 | 0.0438 | 0.133 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0211 | -0.047 | 0.09 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.27 | 0.598 | 2.71 | log | |
| Odds ratio, group 1 over group 2 | 1.3 | 0.57 | 2.98 | log | |
| Number needed to harm, for one more death from any cause on Ranolazine than on Placebo | 47.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ranolazine | 147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.~Ranolazine: This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks Placebo: 500-1,000 mg po bid for 2 weeks | 14 | 142 | EG000 |
| Group 2 | Placebo | 147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.~Ranolazine: This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks Placebo: 500-1,000 mg po bid for 2 weeks | 11 | 142 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- 6 weeks
Source ClinicalTrials.gov
Trial
- Title
- Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia
- NCT number
- NCT01342029
- Phases
- NA
- Conditions
- Microvascular Coronary Dysfunction (MCD)
- Interventions
- Ranolazine, Placebo
- Lead sponsor
- Cedars-Sinai Medical Center
- Results first posted
- 2017-12-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01342029?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01342029-deaths